[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588622":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":18,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":18,"enrollmentInfo":64,"targetDuration":18,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":18,"overallStatus":73,"whyStopped":18,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Fudan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group (high-risk Hp subtype guidance + eradication treatment)","EXPERIMENTAL","The guidance team, consisting of the attending physician and trial-related personnel, will conduct individualized assessments and education based on factors such as Hp infection, SNP results, gastric mucosa condition, and medical history, and provide eradication treatment recommendations.",[13],"Drug: recommendations for Hp eradication treatment",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group (routine Hp management)","NO_INTERVENTION","According to the routine management of HP infected patients, symptomatic relief treatment will be provided, and no intervention guidance from the 'high-risk Hp subtype guidance group' will be given.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","recommendations for Hp eradication treatment","A high-risk Hp subtype guidance group consisting of the receiving physician + trial-related personnel conducts individualized assessment based on Hp infection, SNP test results, gastric mucosa condition, medical history and other factors, and provides subjects with medical explanations and recommendations for eradication treatment.\n\nEradication group protocol: standard quadruple therapy for H. pylori eradication program (PPI + bismuth + two antibiotics)\n\n1. Omeprazole (or esomeprazole): 20mg, 2 times\u002Fday\n2. Bismuth citrate: 220mg, 2 times\u002Fday\n3. Metronidazole: 400mg, 3 times\u002Fday\n4. Tetracycline: 500mg, 3 times\u002Fday\n5. Treatment cycle: 10-14 days Eradication success was assessed after 1 month by urea breath test (UBT) or Hp fecal antigen test.",[9],[26],"Helicobacter pylori eradication",[28],{"name":29,"role":30,"phone":31,"phoneExt":18,"email":32},"Dazhi Xu, Doctor","CONTACT","086-18121299796","xudzh@fudan.edu.cn",[34],{"facility":35,"status":18,"city":36,"state":18,"zip":18,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"People's Hospital of Tongling City","Tongling","China","CN",{"type":40,"coordinates":41},"Point",[42,43],117.78333,30.95,{"lat":43,"lon":42},[46],{"name":47,"role":30,"phone":48,"phoneExt":18,"email":49},"Guihe Wang","86+05625838104","2175613200@qq.com",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Dazhi Xu","Director of the gastric surgery department","100588622","eradication-of-helicobacter-pylori-subtypes-at-high-gastric-cancer-risk-a-cluster-randomized-controlled-trial-100588622",false,"NCT06943794","Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","Gastric Cancer Prevention Strategies Based on Eradication of Helicobacter Pylori Subtypes at High Risk for Gastric Cancer: a Practical Cluster-randomized Controlled Trial","Inclusion Criteria :\n\n1. Age ≥ 40 years, gender is not limited.\n2. Voluntary participation with signed informed consent.\n3. No H. pylori eradication treatment received within the past 1 month.\n4. Able to complete stool sample collection and related examinations as per study requirements.\n5. Detected as high-risk by Hp subtype test.\n\nExclusion Criteria:\n\n1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.\n2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.\n3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior.\n4. Pregnant or breastfeeding women.\n5. Other conditions that the investigator deems inappropriate for participation in the study.",true,"ALL","40 Years",{"count":65,"type":66},4824,"ESTIMATED","INTERVENTIONAL",[69],"NA","This study is a prospective, multicenter cluster randomized controlled trial. Additional fecal screening for high-risk SNP subtypes, in conjunction with routine Hp testing, may improve the identification of individuals at high risk for gastric cancer. Moreover, the implementation of eradication interventions in high-risk groups has the potential to significantly reduce the incidence and progression of gastric cancer.",[72],"Gastric (Stomach) Cancer","NOT_YET_RECRUITING","2026-02-23",{"date":76,"type":77},"2026-02-25","ACTUAL",{"date":79,"type":66},"2026-03-30",{"date":81,"type":66},"2030-12-30",{"name":5,"class":6},1]